Focused Ultrasound For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Focused Ultrasound (FUS) is a non-invasive therapeutic technology that uses acoustic energy to precisely target brain regions for treatment of neurodegenerative diseases. It offers a unique combination of thermal ablation, blood-brain barrier (BBB) opening, and neuromodulation without surgical intervention.
- Mechanism: Thermal ablation through focused acoustic energy
- Applications: Thalamotomy for tremor, target ablation in movement disorders
- FDA Approved: Essential tremor, Parkinson's disease tremor
- Mechanism: Neuromodulation without tissue heating
- Applications: Non-invasive brain stimulation
- Research Stage: Clinical trials ongoing
- Mechanism: Acoustic cavitation opens blood-brain barrier
- Applications: Drug delivery, biomarker release
- Clinical Trials: AD, PD, ALS
| Condition |
Target |
Evidence |
| Parkinson's Disease (tremor) |
VIM thalamus |
FDA approved |
| Parkinson's Disease (bradykinesia) |
STN, GPi |
Phase III |
| Essential Tremor |
VIM thalamus |
FDA approved |
| Dystonia |
GPi, STN |
Phase II/III |
- Amyloid Clearance: FUS-BBBO enhances antibody delivery
- Aβ Reduction: Direct mechanical disruption of plaques
- Neuroinflammation: Modulation of microglial activation
- Biomarker Release: Collects AD biomarkers via BBB opening
- Amyotrophic Lateral Sclerosis (ALS): Motor cortex application
- Multiple Sclerosis: Myelin repair enhancement
- Brain Tumors: Drug delivery enhancement
- Protein denaturation at temperatures >55°C
- Coagulation necrosis of targeted tissue
- Precise lesioning with sub-millimeter accuracy
- Transient opening of endothelial tight junctions
- Enhanced delivery of therapeutic agents
- Duration: 4-6 hours typically
- Repeat treatments possible
- Neuronal excitation or inhibition
- Modulation of neural circuits
- Non-invasive alternative to DBS
- Phase III Trial: 76% tremor reduction at 1 year
- FDA Approval: 2016 for essential tremor
- Durability: Sustained benefit through 5 years
- Phase III Trial: Significant OFF-medication tremor reduction
- Motor Complications: Improved quality of life
- Comparison: Non-inferior to DBS in selected patients
- Phase I Trial: Safe BBB opening, reduced Aβ plaques
- Phase II Trial: Improved cognition with anti-amyloid antibodies
- Ongoing: Multi-center trials
- MRI for targeting
- Skull CT for bone correction
- Patient screening for eligibility
- Anesthesia or sedation as needed
- Stereotactic frame placement
- Real-time MRI guidance
- Sonications (30-60 seconds each)
- Temperature monitoring
- Clinical monitoring
- MRI to confirm lesion/treatment
- Neurological assessment
- Follow-up imaging
- Rehabilitation if needed
| Combination |
Rationale |
| FUS + Anti-amyloid antibodies |
Enhanced Aβ clearance |
| FUS + Chemotherapy |
Better brain tumor delivery |
| FUS + Gene therapy |
AAV delivery across BBB |
| FUS + Immunotherapy |
Enhanced CNS immune response |
- Headache (transient)
- Dizziness
- Mild confusion
- Scalp discomfort
- Intracranial hemorrhage
- Thermal injury to off-target tissue
- Permanent neurological deficits (<1%)
- Edema at treatment site
- Metallic implants in treatment path
- Uncontrolled hypertension
- Coagulopathy
- Pregnancy
The study of Focused Ultrasound For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [1] Elias WJ, et al. A randomized trial of focused ultrasound thalamotomy for essential tremor. N Engl J Med. 2016;375(8):730-739.
- [2] Martinez-Fernandez R, et al. Focused ultrasound as a non-invasive treatment for Parkinson's disease. Mov Disord. 2020;35(9):1584-1593.
- [3] Lipsman N, et al. Blood-brain barrier opening in Alzheimer's disease using MR-guided focused ultrasound. Nat Commun. 2018;9(1):2336.
- [4] Rezai AR, et al. Noninvasive deep brain stimulation for Alzheimer's disease. J Neurosurg. 2020;133(5):1534-1543.
- [5] Magara A, et al. First experience with MR-guided focused ultrasound in the treatment of Parkinson's disease. J Ther Ultrasound. 2014;2:11.
- [6] Tychy A, et al. Focused ultrasound in neurodegenerative disorders: mechanisms and clinical applications. Brain Stimul. 2021;14(5):1138-1148.
- [7] Meng Y, et al. MR-guided focused ultrasound for opening the blood-brain barrier. Radiology. 2021;299(2):331-342.
- [8] Downs ME, et al. Long-term safety of repeated blood-brain barrier opening in Alzheimer's disease. J Ther Ultrasound. 2021;9(1):1-14.